Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
321-340 of 2,251 trials

Growth Hormone Deficiency: LUM-201 Treatment Study

We are monitoring the long-term safety of LUM-201 in children with idiopathic growth hormone deficiency. This study also looks at how the treatment affects growth and related health markers.

Idiopathic Growth Hormone Deficiency>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesEndocrinologyPediatrics

Breast Cancer Surgery: ICG Imaging Study

We are exploring how a special imaging technique using ICG dye can help surgeons evaluate cancer margins during breast-conserving surgery. This study aims to find the best timing and dose for the dye to improve surgical outcomes.

Early Invasive Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

[18F]PSMA-1007 PET/CT Imaging for Prostate Cancer

We are studying how well a new imaging method detects cancer spread in patients with newly diagnosed high-risk prostate cancer. This could help improve diagnosis and treatment planning.

Prostate Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Botulinumtoxin A for Myofascial Pain in Temporomandibular Disorders

We are studying whether BTX injections in jaw muscles can effectively reduce pain in patients with temporomandibular disorders. This research may help improve treatment options for those suffering from this condition.

Temporomandibular DisorderConfirmation phase (III)No PlaceboStandard MedicinesOrthopedics and TraumatologyOtolaryngology

Guselkumab for Crohn's Disease Healing

We are studying whether guselkumab can help heal the intestinal wall in patients with Crohn's disease. This research aims to find out how effective it is over 48 weeks.

Crohn's Disease>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Dapagliflozin for Heart Health in Amyloid Transthyretin Cardiac Amyloidosis

We are studying how dapagliflozin may improve exercise capacity and quality of life for patients with ATTR-CA. This trial will also look at its safety and other health markers.

Cardiac Amyloidosis1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Chronic Lymphocytic Leukemia: Tailored Ibrutinib Treatment

We are studying how personalized dosing of ibrutinib can improve treatment for patients with previously untreated chronic lymphocytic leukemia. The goal is to see if adjusting the dose based on side effects leads to better outcomes.

Chronic Lymphocytic Leukemia (CLL)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Personalized Anti-Platelet Therapy for Coronary Artery Disease

We are studying whether a genetic test-guided treatment improves blood platelet function in patients with stable coronary artery disease undergoing stenting. This may help determine the best anti-platelet therapy for individual patients.

Stable Coronary Artery DiseaseChronic Coronary Syndrome3-6 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Alectinib for Pediatric ALK Fusion-Positive Tumors

We are studying the safety and effectiveness of alectinib in children with solid or CNS tumors that have not responded to other treatments. This trial aims to find the best dose and understand how the drug works in young patients.

Malignant Mast Cell TumorsALK Fusion-Positive Tumors>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPediatrics

Nicotinamide for Liver Fibrosis in Type 2 Diabetes

We are studying whether nicotinamide can help slow liver fibrosis in people with type 2 diabetes. The trial will also assess safety and other health factors related to obesity.

Hepatic Fibrosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesDiabetologyEndocrinologyHepatology

Hunter Syndrome: Long-Term Safety of Idursulfase-IT and Elaprase®

We are studying the long-term safety of a treatment combining intrathecal idursulfase-IT and intravenous Elaprase® for individuals with Hunter syndrome and cognitive impairment. This research aims to ensure the safety of these therapies over time.

Hunter's SyndromeConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyInternal MedicineNeurology

Breast Cancer: Stopping CDK4/6 Inhibitors

We are studying whether stopping CDK4/6 inhibitors helps maintain disease stability in patients with metastatic HR positive, HER2 negative breast cancer. This trial involves patients who have had stable disease after long-term treatment.

Metastatic HR Positive, HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Esophageal Cancer: Preventing Infections After Surgery

We are studying whether a special treatment can reduce the risk of pneumonia and other infections in patients undergoing surgery for esophageal cancer. This may help improve recovery and overall health after the procedure.

Esophageal Cancer3-6 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesGastroenterologyInfectious DiseasesOncologyPulmonology

Endometrial Cancer: NEPA for Nausea Relief

We are studying whether a single dose of NEPA can effectively prevent nausea and vomiting in patients with endometrial cancer receiving chemotherapy. This trial also assesses the safety of NEPA and its effects on patients' quality of life.

Chemotherapy-Induced Nausea and Vomiting Prophylaxis≤3 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesInternal MedicineOncology

Alzheimer's Disease: KarXT Medication Study

We are examining how well the medication KarXT is tolerated over a long period in people with psychosis related to Alzheimer's disease. This study aims to ensure the safety of this treatment for participants.

Psychosis Associated with Alzheimer's Disease1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPsychiatry

Advanced Ovarian Cancer: Comparing Treatment Combinations

We are studying two different drug combinations to see which one helps patients with advanced ovarian cancer live longer without disease progression after surgery. This trial involves patients who have undergone complete initial surgery.

Advanced Ovarian Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Atopic Eczema: Dupilumab Dosing Study

We are studying how different dosing schedules of dupilumab affect people with controlled atopic eczema. The goal is to see which schedule works best for managing symptoms and improving quality of life.

Atopic Eczema3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteAllergologyDermatology

Advanced Breast Cancer: Saruparib and Camizestrant Study

We are studying a new combination treatment for adults with advanced hormone receptor-positive, HER2-negative breast cancer. The goal is to see if it helps patients live longer without disease progression compared to standard therapies.

Advanced Breast CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyOncology

Fertility Treatment: Natural Progesterone vs. GnRH Antagonists

We are comparing a natural progesterone treatment to a standard injectable medication for women undergoing ovarian stimulation. The goal is to see which method is more effective and cost-efficient in preventing hormonal surges.

Women Undergoing Ovarian Stimulation for Oocyte DonationMonitoring phase (IV)No PlaceboInvestigational MedicinesGynecology and Obstetrics

Metastatic Melanoma: Diclofenac with PD-1 Inhibitor

We are studying whether adding diclofenac to ongoing PD-1 inhibitor therapy helps patients with metastatic melanoma who have stable disease. This trial aims to evaluate the potential benefits of this combination treatment.

Metastatic Melanoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesDermatologyOncology